Therapeutics News and Research

RSS

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones. Enzon will also receive royalties of 5 to 10 percent on incremental net sales above a 2009 baseline amount from Enzon’s four marketed specialty pharmaceutical products through 2014.

9 Nov 2009

Ikano Therapeutics' midazolam granted Orphan Drug designation

Ikano Therapeutics, Inc. announced today that it has received Orphan Drug designation for midazolam in the acute treatment of certain forms of epileptic seizure known as cluster seizures or alternatively, as acute repetitive seizures.

9 Nov 2009

Cytori Therapeutics announces financial results for the third quarter of 2009

Cytori Therapeutics is reporting its financial results for the quarter and nine months ended September 30, 2009.

9 Nov 2009

BrainStorm Cell Therapeutics' approach for treating neurodegenerative diseases shown to be effective

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases was shown to be superior to other current potential stem cell treatments.

9 Nov 2009

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.

9 Nov 2009

Nasdaq grants Anesiva's request for continued listing on The NASDAQ Global Market

Anesiva, Inc. today announced that on November 5, 2009, it received a letter from The NASDAQ Stock Market LLC stating that the Nasdaq Hearing Panel has granted Anesiva's request for continued listing on The NASDAQ Global Market subject to the condition that Anesiva shall have completed on or before December 31, 2009, the proposed merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated August 4, 2009, among Anesiva, Arca Acquisition Corporation ("Arca"), a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") and, with respect to Articles V and IX only of the agreement, each of the Arcion stockholders listed on Schedule I thereto.

9 Nov 2009

Financial results for the third-quarter announced by Repros Therapeutics

Repros Therapeutics today announced financial results for the third quarter ended September 30, 2009.

9 Nov 2009

Researchers discover a fungal protein that causes disease in plants and animals

Researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech and Montana State University have discovered a fungal protein that plays a key role in causing disease in plants and animals and which also shields the pathogen from oxidative stress.

7 Nov 2009

Halozyme Therapeutics announces results of its insulin variability study

Halozyme Therapeutics, Inc. today announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro alone.

7 Nov 2009

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009.

6 Nov 2009

Results of LightTouch Non-invasive Cervical Cancer Detection Device trial presented

Results of the FDA pivotal clinical trial for the LightTouch™ Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI).

6 Nov 2009

Arthur H. Rubenstein to receive the Abraham Flexner Award

Arthur H. Rubenstein, MBBCh, Executive Vice President of the University of Pennsylvania for the Health System, and Dean, School of Medicine, will receive the Abraham Flexner Award for Distinguished Service to Medical Education from the Association of American Medical Colleges (AAMC).

6 Nov 2009

William D. Carey Award for Boston University School of Medicine professor

Francis A. Farraye, MD, MSc, FACG, FASGE, a professor of medicine at Boston University School of Medicine (BUSM) and clinical director in the Gastroenterology Section at Boston Medical Center (BMC) recently received the William D. Carey Award from the American College of Gastroenterology (ACG). The award is reserved for an exceptional individual who has served the Board and the College with distinction.

5 Nov 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.

5 Nov 2009

Atrium Medical presents final results of its "COCTAIL study"

Atrium Medical Corporation is proud to announce the release of the final results of the "COCTAIL Study," a clinical study comparing local administration of an anti-platelet medication with the company's proprietary infusion balloon technology.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.

5 Nov 2009

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies demonstrating that human Serum Amyloid P (hSAP) potently inhibited fibrosis in two independent model systems of kidney fibrosis.

5 Nov 2009

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $208 million to two programs that support research to better understand the human immune response to emerging and re-emerging infectious diseases, including those that may be introduced into a community through acts of bioterrorism.

5 Nov 2009

Therapeutics News and Research

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Ikano Therapeutics' midazolam granted Orphan Drug designation

Cytori Therapeutics announces financial results for the third quarter of 2009

BrainStorm Cell Therapeutics' approach for treating neurodegenerative diseases shown to be effective

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

Nasdaq grants Anesiva's request for continued listing on The NASDAQ Global Market

Financial results for the third-quarter announced by Repros Therapeutics

Researchers discover a fungal protein that causes disease in plants and animals

Halozyme Therapeutics announces results of its insulin variability study

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Results of LightTouch Non-invasive Cervical Cancer Detection Device trial presented

Arthur H. Rubenstein to receive the Abraham Flexner Award

William D. Carey Award for Boston University School of Medicine professor

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Atrium Medical presents final results of its "COCTAIL study"

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News